<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2827">
  <stage>Registered</stage>
  <submitdate>24/06/2010</submitdate>
  <approvaldate>24/06/2010</approvaldate>
  <nctid>NCT01150890</nctid>
  <trial_identification>
    <studytitle>AMG 827 in Subjects With Moderate to Severe Crohn's Disease</studytitle>
    <scientifictitle>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20090072</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Crohn's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Crohn's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AMG 827 350 MG
Treatment: drugs - AMG 827 210 MG
Treatment: drugs - AMG 827 700 MG
Treatment: drugs - Placebo

Experimental: AMG 827 IV 350 MG - 350 mg AMG 827

Experimental: AMG 827 IV 700 MG - 700 mg AMG 827

Placebo Comparator: PLACEBO - Placebo

Experimental: AMG 827 IV 210 MG - 210 mg AMG 827


Treatment: drugs: AMG 827 350 MG
350 mg AMG 827 IV (in the vein)

Treatment: drugs: AMG 827 210 MG
210 mg AMG 827 IV (in the vein)

Treatment: drugs: AMG 827 700 MG
700 mg AMG 827 IV (in the vein)

Treatment: drugs: Placebo
Placebo IV (in the vein)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the efficacy of AMG 827 compared with placebo as measured by the proportion of subjects achieving Crohn's Disease Activity Index (CDAI) remission (= 150) at week 6.</outcome>
      <timepoint>6 Weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the efficacy of AMG 827 as measured by the proportion of subjects with a CDAI response (reduction from baseline of = 100) at week 6</outcome>
      <timepoint>6 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate improvement from baseline in CDAI at week 6</outcome>
      <timepoint>6 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the short term safety profile of AMG 827 in subjects with Crohn's disease</outcome>
      <timepoint>12 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To characterize the pharmacokinetics (PK) of AMG 827 in subjects with Crohn's disease</outcome>
      <timepoint>6 Weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosed with ileal, ileo-colonic, or colonic Crohn's disease for a minimum of 6
             months prior to initiating Study Product

          -  Moderately to severely active Crohn's disease, as defined by a CDAI score &gt;250 and
             &lt;450 at baseline

          -  Evidence of active inflammation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Short bowel syndrome

          -  Stricture with obstructive symptoms within 3 months

          -  Bowel surgery within 3 months

          -  Ileostomy and/or colostomy

          -  Any gastric or intestinal pouch

          -  Ulcerative colitis

          -  Evidence of an infected abscess

          -  Bowel perforation or evidence of noninflammatory obstruction during the 6 months Stool
             positive for C. Difficile toxin at screening

          -  Presence of active infection requiring treatment

          -  Serious infection within 8 weeks

          -  Significant concurrent medical conditions

          -  Pregnant or breast feeding

          -  Significant Laboratory abnormalities

          -  Any anti-TNF agent within 2 months

          -  Steroid enemas within 2 weeks

          -  Tysabri (natalizumab) within 1 year

          -  Biologic agents (eg, ustekinumab), experimental procedures, or live vaccines within 3
             months

          -  Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin),thalidomide or tacrolimus
             within 2 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>130</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Research Site - Kurralta Park</hospital>
    <hospital>Research Site - Box Hill</hospital>
    <hospital>Research Site - Fitzroy</hospital>
    <hospital>Research Site - Fremantle</hospital>
    <postcode> - Kurralta Park</postcode>
    <postcode> - Box Hill</postcode>
    <postcode> - Fitzroy</postcode>
    <postcode> - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bonheiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Roeselare</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice Cedex 3</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 10</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse Cedex 09</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Olsztyn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Opole</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Sopot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Galicia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will examine the safety and effectiveness of AMG 827 for the treatment of moderate
      to severe Crohn's disease. Patients will randomly receive either AMG 827 or placebo (a
      lookalike liquid that doesn't have any drug in it) and neither the doctor nor the patient
      will know what treatment is being given.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01150890</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>